|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NUDT19 |
Gene summary for NUDT19 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NUDT19 | Gene ID | 390916 |
| Gene name | nudix hydrolase 19 | |
| Gene Alias | RP2 | |
| Cytomap | 19q13.11 | |
| Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | A8MXV4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 390916 | NUDT19 | C04 | Human | Oral cavity | OSCC | 9.35e-11 | 5.20e-01 | 0.2633 |
| 390916 | NUDT19 | C21 | Human | Oral cavity | OSCC | 1.40e-03 | 2.39e-01 | 0.2678 |
| 390916 | NUDT19 | C30 | Human | Oral cavity | OSCC | 3.23e-23 | 8.07e-01 | 0.3055 |
| 390916 | NUDT19 | C38 | Human | Oral cavity | OSCC | 1.41e-05 | 6.31e-01 | 0.172 |
| 390916 | NUDT19 | C43 | Human | Oral cavity | OSCC | 2.34e-12 | 3.05e-01 | 0.1704 |
| 390916 | NUDT19 | C46 | Human | Oral cavity | OSCC | 9.71e-13 | 2.90e-01 | 0.1673 |
| 390916 | NUDT19 | C57 | Human | Oral cavity | OSCC | 1.27e-03 | 1.89e-01 | 0.1679 |
| 390916 | NUDT19 | C08 | Human | Oral cavity | OSCC | 1.84e-07 | 2.32e-01 | 0.1919 |
| 390916 | NUDT19 | C09 | Human | Oral cavity | OSCC | 1.75e-02 | 1.05e-01 | 0.1431 |
| 390916 | NUDT19 | LN38 | Human | Oral cavity | OSCC | 1.43e-03 | 5.82e-01 | 0.168 |
| 390916 | NUDT19 | LP15 | Human | Oral cavity | LP | 2.62e-02 | 5.27e-01 | 0.2174 |
| 390916 | NUDT19 | SYSMH1 | Human | Oral cavity | OSCC | 3.35e-05 | 1.58e-01 | 0.1127 |
| 390916 | NUDT19 | SYSMH2 | Human | Oral cavity | OSCC | 2.36e-10 | 2.40e-01 | 0.2326 |
| 390916 | NUDT19 | SYSMH3 | Human | Oral cavity | OSCC | 1.15e-11 | 2.81e-01 | 0.2442 |
| 390916 | NUDT19 | SYSMH6 | Human | Oral cavity | OSCC | 2.97e-02 | 6.59e-02 | 0.1275 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003465517 | Oral cavity | OSCC | nucleobase-containing compound catabolic process | 244/7305 | 407/18723 | 5.38e-18 | 5.49e-16 | 244 |
| GO:004670015 | Oral cavity | OSCC | heterocycle catabolic process | 254/7305 | 445/18723 | 5.07e-15 | 3.31e-13 | 254 |
| GO:004427016 | Oral cavity | OSCC | cellular nitrogen compound catabolic process | 256/7305 | 451/18723 | 9.67e-15 | 5.88e-13 | 256 |
| GO:001943915 | Oral cavity | OSCC | aromatic compound catabolic process | 263/7305 | 467/18723 | 1.49e-14 | 8.84e-13 | 263 |
| GO:190136115 | Oral cavity | OSCC | organic cyclic compound catabolic process | 272/7305 | 495/18723 | 2.73e-13 | 1.36e-11 | 272 |
| GO:000675318 | Oral cavity | OSCC | nucleoside phosphate metabolic process | 247/7305 | 497/18723 | 6.28e-07 | 8.96e-06 | 247 |
| GO:000911719 | Oral cavity | OSCC | nucleotide metabolic process | 243/7305 | 489/18723 | 7.80e-07 | 1.09e-05 | 243 |
| GO:001969319 | Oral cavity | OSCC | ribose phosphate metabolic process | 199/7305 | 396/18723 | 2.97e-06 | 3.64e-05 | 199 |
| GO:000925919 | Oral cavity | OSCC | ribonucleotide metabolic process | 189/7305 | 385/18723 | 3.18e-05 | 2.87e-04 | 189 |
| GO:00090627 | Oral cavity | OSCC | fatty acid catabolic process | 59/7305 | 100/18723 | 3.99e-05 | 3.48e-04 | 59 |
| GO:00067905 | Oral cavity | OSCC | sulfur compound metabolic process | 168/7305 | 339/18723 | 4.50e-05 | 3.84e-04 | 168 |
| GO:007252120 | Oral cavity | OSCC | purine-containing compound metabolic process | 199/7305 | 416/18723 | 1.34e-04 | 9.53e-04 | 199 |
| GO:000915020 | Oral cavity | OSCC | purine ribonucleotide metabolic process | 178/7305 | 368/18723 | 1.45e-04 | 1.02e-03 | 178 |
| GO:00066317 | Oral cavity | OSCC | fatty acid metabolic process | 186/7305 | 390/18723 | 2.65e-04 | 1.69e-03 | 186 |
| GO:000616320 | Oral cavity | OSCC | purine nucleotide metabolic process | 188/7305 | 396/18723 | 3.31e-04 | 2.04e-03 | 188 |
| GO:19011361 | Oral cavity | OSCC | carbohydrate derivative catabolic process | 89/7305 | 172/18723 | 4.52e-04 | 2.73e-03 | 89 |
| GO:00723296 | Oral cavity | OSCC | monocarboxylic acid catabolic process | 66/7305 | 122/18723 | 5.02e-04 | 2.95e-03 | 66 |
| GO:00442826 | Oral cavity | OSCC | small molecule catabolic process | 174/7305 | 376/18723 | 2.25e-03 | 1.00e-02 | 174 |
| GO:00338654 | Oral cavity | OSCC | nucleoside bisphosphate metabolic process | 66/7305 | 128/18723 | 2.58e-03 | 1.13e-02 | 66 |
| GO:00338754 | Oral cavity | OSCC | ribonucleoside bisphosphate metabolic process | 66/7305 | 128/18723 | 2.58e-03 | 1.13e-02 | 66 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa041466 | Oral cavity | OSCC | Peroxisome | 47/3704 | 82/8465 | 9.01e-03 | 2.01e-02 | 1.03e-02 | 47 |
| hsa0414611 | Oral cavity | OSCC | Peroxisome | 47/3704 | 82/8465 | 9.01e-03 | 2.01e-02 | 1.03e-02 | 47 |
| hsa0414621 | Oral cavity | LP | Peroxisome | 33/2418 | 82/8465 | 1.48e-02 | 4.69e-02 | 3.03e-02 | 33 |
| hsa0414631 | Oral cavity | LP | Peroxisome | 33/2418 | 82/8465 | 1.48e-02 | 4.69e-02 | 3.03e-02 | 33 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NUDT19 | insertion | Frame_Shift_Ins | novel | c.894_895insACCTGGAAAAGCAGCAGGCACTCAAAGCTAGCTCATGAAAGCA | p.Ala299ThrfsTer16 | p.A299Tfs*16 | A8MXV4 | protein_coding | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | ||
| NUDT19 | SNV | Missense_Mutation | c.969N>T | p.Met323Ile | p.M323I | A8MXV4 | protein_coding | tolerated(0.13) | benign(0.024) | TCGA-C5-A7CG-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| NUDT19 | SNV | Missense_Mutation | rs760397233 | c.925G>A | p.Asp309Asn | p.D309N | A8MXV4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| NUDT19 | SNV | Missense_Mutation | c.988G>A | p.Glu330Lys | p.E330K | A8MXV4 | protein_coding | deleterious(0.03) | probably_damaging(0.996) | TCGA-UC-A7PG-06 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | PD | |
| NUDT19 | SNV | Missense_Mutation | c.1085N>G | p.His362Arg | p.H362R | A8MXV4 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| NUDT19 | SNV | Missense_Mutation | rs371407959 | c.1040G>A | p.Arg347His | p.R347H | A8MXV4 | protein_coding | tolerated(0.45) | benign(0.015) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| NUDT19 | SNV | Missense_Mutation | rs371407959 | c.1040N>A | p.Arg347His | p.R347H | A8MXV4 | protein_coding | tolerated(0.45) | benign(0.015) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| NUDT19 | SNV | Missense_Mutation | novel | c.874N>A | p.Leu292Met | p.L292M | A8MXV4 | protein_coding | tolerated(0.51) | benign(0.085) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NUDT19 | SNV | Missense_Mutation | novel | c.964C>A | p.Leu322Ile | p.L322I | A8MXV4 | protein_coding | tolerated(0.4) | benign(0.003) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| NUDT19 | SNV | Missense_Mutation | rs201248318 | c.782N>C | p.Phe261Ser | p.F261S | A8MXV4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EY-A1G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |